Hajime Uno

Research Scientist
This email address is being protected from spambots. You need JavaScript enabled to view it.



Dr. Hajime Uno's research activities include statistical support for clinical trials and
laboratory study in collaboration with investigators from the Eastern Cooperative Oncology Group's Myeloma Committee and Harvard University Center for AIDS research. His methodological research focuses on evaluating prediction models for clinical outcomes based on standard clinical parameter and biomarkers and on assessing incremental value of new risk scoring systems.



Dr. Uno worked for Takeda, one of pharmaceutical company in Japan, as a statistician to support clinical trials for new drug approval, from 1994 to 2003. The disease area he worked on there include breast cancer, diabetes, and cardiovascular disease and so on. In 2003, he received his PhD in Biostatistics from Kitasato University Graduate School, Tokyo, Japan. He then did a postdoc for a few years at Harvard School of Public Health under the direction of Profs. LJ Wei and Steve Lagakos. He then went back to Japan and joined the faculty of Kitasato University, and then visited Harvard again and became a Research Scientist in the Department of Biostatistics and Computational Biology at Dana-Farber Cancer Institute in 2008. His collaborative work at Dana-Farber is mainly in multiple myeloma studies with the Eastern Cooperative Oncology Group and laboratory study with investigators from Center for AIDS research.


Select Publication

[method paper]
Uno, H., Tian, L. and Wei, L.J. (2005). The optimal confidence region for a random
parameter, Biometrika, 92, 957-64.

Uno, H., Cai, T., Tian, L. and Wei, L.J. (2007). Evaluating prediction rules for t-year
survivors with censored regression models, Journal of the American Statistical
Association, 102 (478), 527-537.

Li, L., Evans, S., Uno, H., and Wei, L.J. (2009). Predicted Interval Plots (PIPS): A
Graphical Tool for Data Monitoring of Clinical Trials, Statistics in Biopharmaceutical
Research, 1(4), 348-355.

Cai, T., Tian, L., Uno, H., Solomon, S. D., and Wei, L.J. (2010). Calibrating Parametric
Subject-Specific Risk Estimation, Biometrika (accepted)

[cancer research]
Tateishi, U., Uno, H., Yonemori, K., Satake, M., Takeuchi, M. and Arai, Y. (2005)
Prediction of lung adenocarcinoma without vessel invasion: A CT volumetric analysis,
Chest, 128, 3276-83.

Yonemori, K., Katsumata, N., Kaneko, M., Uno, H., Matsumoto, K., Kouno, T., Shimizu, C., Ando, M., Takeuchi, M., Fujiwara, Y. (2007). Prediction of response to repeat utilization of anthracyline in recurrent breast cancer patients previously administered anthracyline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy, Breast Cancer Research Treatment, 103(3), 313-318.

Yonemori, K., Katsumata, N., Noda A, Uno, H., Yunokawa, M., Nakano, E., Kouno, T., Shimizu, C., Ando, M., Tamura, K., Takeuchi, M., Fujiwara, Y. (2008). Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer, Journal of Cancer Research and Clinical Oncology, 134:1199-206.

Gertz, M. A., Abonour, R., Heffner, T., Greipp, P. R., Uno, H. , Rajikumar, V. (2009).
Clinical Value of Minor Responses After 4 Doses of Rituximab in Waldenstrom
Macroglobulinemia: A Follow-Up of the Eastern Cooperative Oncology Group E3A98 Trial, British Journal of Haematology, 147(5): 677-680.

[cardiovascular research]
Meris, A., Amigoni, M., Uno, H., Thune, J. J., Verma, A., Kober, L., Bourgoun, M., McMurray, J. J., Velazquez, E. J., Maggioni, A. P., Ghali, J., Arnold, J. M., Zelenkofske, S., Pfeffer, M. A., Solomon, S. D. (2009). Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. Eur Heart J, 30:56-65.

Shin, SH, Huan, CL, Uno, H., Hassanein, A. H., Verma, A., Bourgoun, M., K¿ber, L., Ghali, J. K., Velazquez, E. J., Califf, R. M., Pfeffer, M. A., Solomon, S. D. for the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Mechanical Dyssynchrony after Myocardial Infarction in Patients with Left Ventricular Dysfunction, Heart Failure, or Both, Circulation, 2010, online ahead of print.


Related Links

Personal Page

Eastern Cooperative Oncology Group (ECOG)

Harvard University Center for AIDS Research (CFAR)

Department of Biostatstics, Harvard University